

Yoichi Imai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3802788/publications.pdf>

Version: 2024-02-01

131
papers

3,448
citations

126907

33
h-index

155660

55
g-index

137
all docs

137
docs citations

137
times ranked

4814
citing authors

#	ARTICLE	IF	CITATIONS
1	The corepressor CtBP interacts with Evi-1 to repress transforming growth factor β^2 signaling. <i>Blood</i> , 2001, 97, 2815-2822.	1.4	214
2	Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. <i>Journal of Experimental Medicine</i> , 2011, 208, 2403-2416.	8.5	157
3	Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. <i>Blood</i> , 2000, 96, 3154-3160.	1.4	152
4	The Extracellular Signal-Regulated Kinase Pathway Phosphorylates AML1, an Acute Myeloid Leukemia Gene Product, and Potentially Regulates Its Transactivation Ability. <i>Molecular and Cellular Biology</i> , 1996, 16, 3967-3979.	2.3	142
5	Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. <i>Blood</i> , 2011, 117, 3617-3628.	1.4	129
6	Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. <i>International Journal of Hematology</i> , 2009, 89, 592-599.	1.6	116
7	Influence of Pretransplantation Serum Ferritin on Nonrelapse Mortality after Myeloablative and Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 195-204.	2.0	113
8	TLE, the Human Homolog of Groucho, Interacts with AML1 and Acts as a Repressor of AML1-Induced Transactivation. <i>Biochemical and Biophysical Research Communications</i> , 1998, 252, 582-589.	2.1	101
9	The t(3;21) Fusion Product, AML1/Evi-1, Interacts With Smad3 and Blocks Transforming Growth Factor- β^2 -Mediated Growth Inhibition of Myeloid Cells. <i>Blood</i> , 1998, 92, 4003-4012.	1.4	97
10	Distinct roles for LFA-1 affinity regulation during T-cell adhesion, diapedesis, and interstitial migration in lymph nodes. <i>Blood</i> , 2010, 115, 1572-1581.	1.4	91
11	AML1 Is Functionally Regulated through p300-mediated Acetylation on Specific Lysine Residues. <i>Journal of Biological Chemistry</i> , 2004, 279, 15630-15638.	3.4	87
12	Mutations of the Smad4 gene in acute myelogenous leukemia and their functional implications in leukemogenesis. <i>Oncogene</i> , 2001, 20, 88-96.	5.9	83
13	The Corepressor mSin3A Regulates Phosphorylation-Induced Activation, Intranuclear Location, and Stability of AML1. <i>Molecular and Cellular Biology</i> , 2004, 24, 1033-1043.	2.3	80
14	Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. <i>Blood</i> , 2011, 117, 6304-6314.	1.4	79
15	EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization. <i>Leukemia</i> , 2010, 24, 81-88.	7.2	67
16	Notch1 oncoprotein antagonizes TGF β^2 /Smad β -mediated cell growth suppression via sequestration of coactivator p300. <i>Cancer Science</i> , 2005, 96, 274-282.	3.9	65
17	The effect of iron overload and chelation on erythroid differentiation. <i>International Journal of Hematology</i> , 2012, 95, 149-159.	1.6	59
18	Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells. <i>Oncogene</i> , 2009, 28, 4364-4374.	5.9	58

#	ARTICLE	IF	CITATIONS
19	AML1/RUNX1 functions as a cytoplasmic attenuator of NF- κ B signaling in the repression of myeloid tumors. <i>Blood</i> , 2011, 118, 6626-6637.	1.4	54
20	The transcriptionally active form of AML1 is required for hematopoietic rescue of the AML1-deficient embryonic para-aortic splanchnopleural (P-Sp) region. <i>Blood</i> , 2004, 104, 3558-3564.	1.4	53
21	Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies. <i>Cancer Science</i> , 2016, 107, 1543-1549.	3.9	53
22	Predictors for severe cardiac complications after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2004, 33, 1043-1047.	2.4	48
23	The AML1/ETO(MTG8) and AML1/Evi-1 Leukemia-Associated Chimeric Oncoproteins Accumulate PEBP2 β (CBF β) in the Nucleus More Efficiently Than Wild-Type AML1. <i>Blood</i> , 1998, 91, 1688-1699.	1.4	47
24	A Non-Canonical Function of Zebrafish Telomerase Reverse Transcriptase Is Required for Developmental Hematopoiesis. <i>PLoS ONE</i> , 2008, 3, e3364.	2.5	47
25	Male predominance among Japanese adult patients with late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2003, 32, 1175-1179.	2.4	43
26	T cell acute lymphoblastic leukemia arising from familial platelet disorder. <i>International Journal of Hematology</i> , 2010, 92, 194-197.	1.6	43
27	Homeoprotein DLX-1 interacts with Smad4 and blocks a signaling pathway from activin A in hematopoietic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 15577-15582.	7.1	42
28	Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP. <i>Oncogene</i> , 2005, 24, 6165-6173.	5.9	42
29	Essential roles of VLA-4 in the hematopoietic system. <i>International Journal of Hematology</i> , 2010, 91, 569-575.	1.6	41
30	HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action. <i>Cancers</i> , 2019, 11, 475.	3.7	40
31	Mutations of Chk2 in primary hematopoietic neoplasms. <i>Blood</i> , 2002, 99, 3075-3077.	1.4	38
32	The negative impact of female donor/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk. <i>Transplant International</i> , 2011, 24, 469-476.	1.6	35
33	Leukemia-Related Transcription Factor TEL Is Negatively Regulated through Extracellular Signal-Regulated Kinase-Induced Phosphorylation. <i>Molecular and Cellular Biology</i> , 2004, 24, 3227-3237.	2.3	33
34	Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma. <i>JCI Insight</i> , 2016, 1, e85061.	5.0	32
35	Bronchiolitis obliterans organizing pneumonia after syngeneic bone marrow transplantation for acute lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 1997, 19, 1251-1253.	2.4	31
36	The t(3;21) fusion product, AML1/Evi-1 blocks AML1-induced transactivation by recruiting CtBP. <i>Oncogene</i> , 2002, 21, 2695-2703.	5.9	31

#	ARTICLE	IF	CITATIONS
37	Genetic perturbation of the putative cytoplasmic membrane-proximal salt bridge aberrantly activates $\hat{I}\pm 4$ integrins. <i>Blood</i> , 2008, 112, 5007-5015.	1.4	31
38	Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through down-regulation of p19ARF. <i>Blood</i> , 2011, 118, 2541-2550.	1.4	31
39	Intracellular Reactive Oxygen Species Mark and Influence the Megakaryocyte-Erythrocyte Progenitor Fate of Common Myeloid Progenitors. <i>Stem Cells</i> , 2014, 32, 548-557.	3.2	31
40	Functional regulation of TEL by p38-induced phosphorylation. <i>Biochemical and Biophysical Research Communications</i> , 2002, 299, 116-125.	2.1	28
41	Donor cell-derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source. <i>Bone Marrow Transplantation</i> , 2014, 49, 102-109.	2.4	28
42	Clinical impact of serum soluble SLAMF7 in multiple myeloma. <i>Oncotarget</i> , 2018, 9, 34784-34793.	1.8	27
43	Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion. <i>Bone Marrow Transplantation</i> , 2004, 33, 549-552.	2.4	26
44	Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase. <i>Leukemia</i> , 2005, 19, 930-935.	7.2	23
45	HIV \hat{a} €negative, HHV \hat{a} €8 \hat{a} €unrelated primary effusion lymphoma \hat{a} €like lymphoma: report of two cases. <i>American Journal of Hematology</i> , 2010, 85, 85-87.	4.1	23
46	Clinical Significance of Serum-Soluble Interleukin-2 Receptor in Patients With Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 410-416.	0.4	22
47	Functional analysis of a dominant-negative \hat{I} ETS TEL/ETV6 isoform. <i>Biochemical and Biophysical Research Communications</i> , 2004, 317, 1128-1137.	2.1	20
48	Acute eosinophilic pneumonia is a non-infectious lung complication after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2009, 89, 244-248.	1.6	20
49	Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic haematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2010, 45, 1719-1727.	2.4	20
50	Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces MDR1 /P-glycoprotein expression in multidrug resistant leukemic cells and inhibits leukemic cell proliferation. <i>Leukemia Research</i> , 2018, 67, 99-108.	0.8	20
51	Multiple phosphorylation sites are important for $\langle scp \rangle$ RUNX $\langle /scp \rangle$ 1 activity in early hematopoiesis and $\langle scp \rangle$ T $\langle /scp \rangle$ \hat{a} €cell differentiation. <i>European Journal of Immunology</i> , 2012, 42, 1044-1050.	2.9	18
52	Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature. <i>Leukemia and Lymphoma</i> , 2010, 51, 1494-1501.	1.3	17
53	Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 110.	8.6	16
54	An Extended Mathematical Model of Pathophysiology and Response to Treatment in Chronic Myelogenous Leukemia. <i>Blood</i> , 2008, 112, 4220-4220.	1.4	16

#	ARTICLE	IF	CITATIONS
55	Successful Hematopoietic Stem Cell Transplantation from an HLA-Identical Sibling in a Patient with Aplastic Anemia after HLA-Haploidentical Living-Related Liver Transplantation for Fulminant Hepatitis. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 389-390.	2.0	15
56	Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2011, 93, 400-402.	1.6	15
57	Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma. <i>Annals of Hematology</i> , 2010, 89, 207-208.	1.8	14
58	Fatal amebic colitis after high-dose dexamethasone therapy for newly diagnosed multiple myeloma. <i>Annals of Hematology</i> , 2011, 90, 225-226.	1.8	14
59	Clinical efficacy of haematopoietic stem cell transplantation for adult adrenoleukodystrophy. <i>Brain Communications</i> , 2020, 2, fcz048.	3.3	14
60	Identification of a novel fusion gene, TTL, fused to ETV6 in acute lymphoblastic leukemia with t(12;13)(p13;q14), and its implication in leukemogenesis. <i>Leukemia</i> , 2003, 17, 1112-1120.	7.2	13
61	Secondary Syphilis with Tonsillar and Cervical Lymphadenopathy and a Pulmonary Lesion Mimicking Malignant Lymphoma. <i>American Journal of Case Reports</i> , 2018, 19, 238-243.	0.8	13
62	L-Arginine prevents cereblon-mediated ubiquitination of glucokinase and stimulates glucose-6-phosphate production in pancreatic I β -cells. <i>Communications Biology</i> , 2020, 3, 497.	4.4	13
63	Efficacy and Safety of Modified Rituximab-ESHAP Therapy for Relapsed/Refractory B-Cell Lymphoma. <i>Journal of Chemotherapy</i> , 2010, 22, 54-57.	1.5	12
64	Clinical features and outcomes of adult Langerhans cell histiocytosis: a single-center experience. <i>International Journal of Hematology</i> , 2020, 112, 185-192.	1.6	12
65	SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma. <i>Molecular Cancer Research</i> , 2020, 18, 632-643.	3.4	12
66	Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents™ era. <i>Annals of Hematology</i> , 2016, 95, 1465-1472.	1.8	11
67	The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells. <i>PLoS ONE</i> , 2020, 15, e0231896.	2.5	11
68	A Case of Myeloid Sarcoma with Correlation to JAK2V617F Mutation, Complicated by Myelofibrosis and Secondary Acute Myeloid Leukemia. <i>Internal Medicine</i> , 2011, 50, 2649-2652.	0.7	10
69	CD30-positive anaplastic variant diffuse large B cell lymphoma: a rare case presented with cutaneous involvement. <i>International Journal of Hematology</i> , 2010, 92, 550-552.	1.6	9
70	A case of anaplastic large cell lymphoma, ALK positive, primary presented in the skin and relapsed with systemic involvement and leukocytosis after years of follow-up period. <i>International Journal of Hematology</i> , 2010, 92, 667-668.	1.6	9
71	Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine. <i>Leukemia and Lymphoma</i> , 2016, 57, 2204-2207.	1.3	9
72	Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2142-2150.	2.2	9

#	ARTICLE	IF	CITATIONS
73	Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. <i>Blood</i> , 2000, 96, 3154-3160.	1.4	9
74	Evi-1 Is a Direct Target of MLL Oncoproteins in Hematopoietic Stem Cells. <i>Blood</i> , 2008, 112, 3807-3807.	1.4	9
75	CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia. <i>Oncology Letters</i> , 2021, 23, 51.	1.8	9
76	Pharmacokinetics of alemtuzumab after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab with or without CD52-positive malignancies. <i>American Journal of Hematology</i> , 2006, 81, 875-879.	4.1	8
77	High-dose dexamethasone therapy for severe thrombocytopenia and neutropenia induced by EBV infectious mononucleosis. <i>International Journal of Hematology</i> , 2010, 91, 326-327.	1.6	8
78	Concurrent development of Burkitt-like lymphoma and BCL-2-rearranged low-grade B cell lymphoma sharing the same germinal center origin. <i>International Journal of Hematology</i> , 2011, 93, 112-117.	1.6	8
79	Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy. <i>British Journal of Haematology</i> , 2012, 158, 798-800.	2.5	8
80	Expression of activated integrin $\beta 7$ in multiple myeloma patients. <i>International Journal of Hematology</i> , 2021, 114, 3-7.	1.6	8
81	Clinical Significance of Peripheral Blood Erythroblastosis after Hematopoietic Stem Cell Transplantation. <i>Leukemia and Lymphoma</i> , 2004, 45, 2439-2443.	1.3	7
82	A case report of non-traumatic renal artery pseudoaneurysm due to chemotherapy for diffuse large B-cell lymphoma. <i>Annals of Hematology</i> , 2010, 89, 107-108.	1.8	7
83	UGGT1 retains proinsulin in the endoplasmic reticulum in an arginine dependent manner. <i>Biochemical and Biophysical Research Communications</i> , 2020, 527, 668-675.	2.1	7
84	The t(3;21) Fusion Product, AML1/Evi-1, Interacts With Smad3 and Blocks Transforming Growth Factor- β -Mediated Growth Inhibition of Myeloid Cells. <i>Blood</i> , 1998, 92, 4003-4012.	1.4	7
85	Mutational Analyses of the AML1 Gene in Patients with Myelodysplastic Syndrome. <i>Leukemia and Lymphoma</i> , 2002, 43, 617-621.	1.3	6
86	IgG-associated immune thrombocytopenia in Waldenström macroglobulinemia. <i>International Journal of Hematology</i> , 2010, 92, 360-363.	1.6	6
87	Chronic inflammatory demyelinating polyneuropathy in adult T-cell leukemia-lymphoma patients following allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1470-1473.	2.4	6
88	Post-transplant Lymphoproliferative Disorder in Kidney Transplant Recipients: A Single-Center Experience in Japan. <i>Therapeutic Apheresis and Dialysis</i> , 2016, 20, 165-173.	0.9	5
89	The AML1/ETO(MTG8) and AML1/Evi-1 Leukemia-Associated Chimeric Oncoproteins Accumulate PEBP2 β (CBF β) in the Nucleus More Efficiently Than Wild-Type AML1. <i>Blood</i> , 1998, 91, 1688-1699.	1.4	5
90	Fractionated ICE with Rituximab Is Safe and Effective for Relapse/Refractory DLBCL Patients with Severe Comorbidities. <i>Blood</i> , 2015, 126, 2713-2713.	1.4	5

#	ARTICLE	IF	CITATIONS
91	RUNX1 transactivates <i>BCR-ABL1</i> expression in Philadelphia chromosome positive acute lymphoblastic leukemia. <i>Cancer Science</i> , 2022, 113, 529-539.	3.9	5
92	Transient lupus anticoagulant with a prolonged activated partial thromboplastin time secondary to cytomegalovirus-related infectious mononucleosis. <i>Annals of Hematology</i> , 2013, 92, 143-144.	1.8	4
93	Latest Development in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 2544.	3.7	4
94	Should Young Patients with e19a2 Type BCR/ABL Rearrangement Undergo Stem Cell Transplantation?. <i>Leukemia and Lymphoma</i> , 2003, 44, 381-382.	1.3	3
95	Association between thiamine decrease and neuropsychiatric symptoms in gastrointestinal and hematological cancer patients receiving chemotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111929.	5.6	3
96	High Prevalence of Left Ventricular Non-Compaction and Its Effect on Chemotherapy-Related Cardiac Dysfunction in Patients With Hematological Diseases. <i>Circulation Journal</i> , 2020, 84, 1957-1964.	1.6	3
97	Interstitial pneumonia associated with progression of myelodysplastic syndrome. <i>International Journal of Hematology</i> , 2009, 89, 718-719.	1.6	2
98	Clinical Impact and Possible Immunosuppressive Function of Soluble B7-H1 (PD-L1) in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e110-e111.	0.4	2
99	Prospective Analysis of Cytomegalovirus Reactivation and the Immune State of Low-Grade B-Cell Lymphoma Patients Treated with Bendamustine. <i>Blood</i> , 2014, 124, 4411-4411.	1.4	2
100	Histone Deacetylase Inhibitors with or without AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dependent Cytotoxicity As Well As Apoptosis. <i>Blood</i> , 2018, 132, 4435-4435.	1.4	2
101	Successful treatment of secondary NK/T-cell lymphoma of the testis. <i>Annals of Hematology</i> , 2013, 92, 997-998.	1.8	1
102	Nested Polymerase Chain Reaction with Specific Primers for Mucorales in the Serum of Patients with Hematological Malignancies. <i>Japanese Journal of Infectious Diseases</i> , 2019, 72, 196-198.	1.2	1
103	Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities. <i>Annals of Hematology</i> , 2020, 99, 2577-2586.	1.8	1
104	RUNX inhibitor suppresses graft-versus-host disease through targeting RUNX-NFATC2 axis. <i>EJHaem</i> , 2021, 2, 449-458.	1.0	1
105	Thiamine Deficiency and Neurological Symptoms in Patients with Hematological Cancer Receiving Chemotherapy: A Retrospective Analysis. <i>Journal of Neurosciences in Rural Practice</i> , 2021, 12, 726-732.	0.8	1
106	AML1/Runx1 Is a Cytoplasmic Attenuator of NF-Kb Signaling: Implication in Pathogenesis and Targeted Therapy of AML1-Related Leukemia.. <i>Blood</i> , 2009, 114, 1962-1962.	1.4	1
107	Clinical Profile and BRAF Status of 30 Japanese Patients with Adult Langerhans Cell Histiocytosis. <i>Blood</i> , 2016, 128, 4883-4883.	1.4	1
108	Hypersensitivity reaction to β -lactam antibiotics in patients with adult T-cell leukemia/lymphoma treated with mogamulizumab. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2017, 55, 807-810.	0.6	1

#	ARTICLE	IF	CITATIONS
109	Pbx-1 Is a Direct Target of Evi-1 in Hematopoietic Stem/Progenitors and Leukemic Cells.. Blood, 2008, 112, 1192-1192.	1.4	1
110	A Critical Role of Reactive Oxygen Species In the Generation of Megakaryocyte-Erythrocyte Progenitor Cells.. Blood, 2010, 116, 1605-1605.	1.4	1
111	Knockdown of a Wnt Receptor FZD1 reduces MDR1/P-Glycoprotein Expression in Human Leukemia Cells through the Wnt/ β -Catenin Signaling Pathway. Blood, 2014, 124, 2225-2225.	1.4	1
112	Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression. Blood, 2019, 134, 4361-4361.	1.4	1
113	Chronic myelomonocytic leukemia presenting severe uterine hemorrhage due to uterine infiltration of leukemic cells and early-stage endometrial adenocarcinoma. Archives of Gynecology and Obstetrics, 2009, 280, 1077-1078.	1.7	0
114	Serum Soluble SLAMF7 is Correlated With Disease Progression in Multiple Myeloma and May Affect Anti-SLAMF7 Antibody Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e39-e40.	0.4	0
115	Different clonal dynamics of chronic myeloid leukaemia between bone marrow and the central nervous system. British Journal of Haematology, 2018, 183, 842-845.	2.5	0
116	Nonmyelomatous Ascites Resulting from the Increased Secretion of Vascular Endothelial Growth Factor in Multiple Myeloma. Internal Medicine, 2018, 57, 725-727.	0.7	0
117	Prognostic impacts of peripheral blood erythroblasts after single-unit cord blood transplantation. International Journal of Laboratory Hematology, 2021, 43, 1437-1442.	1.3	0
118	P30-1 The influence of thiamine declines on neuropsychiatric symptoms in patients with hematological cancer. Annals of Oncology, 2021, 32, S348.	1.2	0
119	Ki23819 (KRN383-HCl) Inhibits Kinase Activity of Wild Type and Mutant FLT3 Receptor Tyrosine Kinase In Vitro.. Blood, 2004, 104, 1168-1168.	1.4	0
120	Oligomerization of Evi-1 Contributes to Recruitment of Transcriptional Corepressor CtBP and Repression of TGF- β 2 Signaling.. Blood, 2004, 104, 2569-2569.	1.4	0
121	Evi-1 Interacts with Histone Methyltransferases for Transcription Repression and Bone Marrow Transformation.. Blood, 2008, 112, 2257-2257.	1.4	0
122	Impact On Survival and Treatment of Late-Onset Noninfectious Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2009, 114, 3318-3318.	1.4	0
123	Monitoring Trough Concentration of Voriconazole Is Important to Ensure Successful Antifungal Therapy and to Avoid Hepatic Damage in Patients with Hematological Disorders.. Blood, 2009, 114, 4731-4731.	1.4	0
124	Evi1 Is a Stem Cell-Specific Regulator of Self-Renewal Capacity In the Definitive Hematopoietic System. Blood, 2010, 116, 838-838.	1.4	0
125	MLL-HOXA9 and Calcineurin Are Novel Therapeutic Targets in Multiple Myeloma. Blood, 2012, 120, 4007-4007.	1.4	0
126	Interaction Between B7-H1 Molecules on Myeloma Cells and PD-1 Molecules on T Cells Induces Resistance to Antimyeloma Chemotherapy. Blood, 2014, 124, 2018-2018.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Clinical Utility of Slam Family Member CD229 in Identifying Tumor Cells and High-Risk Disease Markers, CD86 (B7-2) and CD126 (IL-6 receptor), Using Flow Cytometric Analysis in Multiple Myeloma. Blood, 2014, 124, 2063-2063.	1.4	0
128	Retrospective Analysis of Treatment Outcomes for Patients with Follicular Lymphoma and Comorbidities. Blood, 2015, 126, 5082-5082.	1.4	0
129	Exploratory Introduction of Cognitive Computing to Clinical Sequencing in Hematological Malignancies. Blood, 2016, 128, 5262-5262.	1.4	0
130	Regulation of Calcineurin Signaling Through Blocking of the Chaperone Function of Hsp90 by HDAC Inhibitors. Heat Shock Proteins, 2019, , 317-328.	0.2	0
131	Therapeutic Targeting of Monokine Production Is a Promising Strategy to Attenuate Cytokine-Release Syndrome in CAR-T Cell Therapy. Blood, 2019, 134, 2067-2067.	1.4	0